{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:04:38Z","timestamp":1794956678940,"version":"4.9.1"},"reference-count":21,"publisher":"Informa UK Limited","issue":"28","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,9,4]]},"DOI":"10.1080\/14796694.2024.2348440","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T03:02:17Z","timestamp":1729479737000},"page":"2059-2070","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2875-6650","authenticated-orcid":false,"given":"Arliene","family":"Ravelo","sequence":"first","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-5677","authenticated-orcid":false,"given":"Kelley","family":"Myers","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0247-474X","authenticated-orcid":false,"given":"Robyn","family":"Brumble","sequence":"additional","affiliation":[{"name":"CLL Society, Inc., Chula Vista, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7854-3596","authenticated-orcid":false,"given":"Cooper","family":"Bussberg","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-8283","authenticated-orcid":false,"given":"Brian","family":"Koffman","sequence":"additional","affiliation":[{"name":"CLL Society, Inc., Chula Vista, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-3465","authenticated-orcid":false,"given":"Beenish S","family":"Manzoor","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M L","family":"Biondo","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-8938","authenticated-orcid":false,"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102468"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30484-8"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153146"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_8_10_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma V.2.2023. \u00a9 National Comprehensive Cancer Network Inc. 2023. All rights reserved. Accessed April 26 2023. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_8_14_1","unstructured":"United States Food and Drug Administration (FDA). Patient preference information\u2014voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling. Guidance for industry Food and Drug Administration staff and other stakeholders [Internet]. 2016 [cited 2023 Mar 28]. Available from: www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-preference-information-voluntary-submission-review-premarket-approval-applications"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007294"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S289139"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000771"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3216"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112971"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145046"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-014-4044-2"},{"key":"e_1_3_8_22_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Leukemia \u2014 Chronic Lymphocytic Leukemia (CLL) [Internet]. 2023 [cited 2024 Feb 15]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"key":"e_1_3_8_23_1","volume-title":"the 64th American Society of Hematology Annual Meeting and Exposition.","author":"Ravelo A","year":"2022","unstructured":"Ravelo A, Myers K, Brumble R, et al. Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments. Poster presented at: the 64th American Society of Hematology Annual Meeting and Exposition. LA, United States: New Orleans; 10\u201313 December 2022."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2348440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T03:03:10Z","timestamp":1729479790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2348440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":21,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2024,9,4]]}},"alternative-id":["10.1080\/14796694.2024.2348440"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2348440","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}